Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure
- Outline
- Approved medications for osteoporosis
- Limitations of current therapy
- Bone structure - normal vs. osteoporosis
- Bone remodeling
- New and emerging treatments
- Dmab inhibits osteoclast formation
- Denosumab indications (USA)
- FREEDOM extension (1)
- FREEDOM extension (2)
- FREEDOM extension summary
- Why BMD continue to increase with Dmab?
- Tissue selective estrogen complexes (TSEC)
- CE/BZA approved by FDA
- Estrogen, progesterone, SERMs
- Combination – sequential therapy
- Transdermal teriparatide
- Transdermal microneedle delivery system
- Oral PTH(1-34)
- 5-CNAC carrier molecule
- Oral recombinant calcitonin
- PTH(1-34) microchip
- Microchip mechanism of action
- Teriparatide reduced risk of vertebral fractures
- Abaloparatide (BA058)
- Abaloparatide phase 2 and 3 studies
- Abaloparatide phase 3 trial (active)
- Risk of VFs fractures: Abalo vs. PBO
- Risk of non-VFs: Abalo vs. PBO
- Abaloparatide-TD
- Wnt signaling pathway
- Romosozumab (AMG 785)
- Romosozumab phase 2 trial
- Cathepsin K
- Cathepsin K inhibitors
- Odanacatib phase 2 trial: 3-year BMD data
- Odanacatib phase 2 trial: bone turnover marker
- Odanacatib phase 3: LOFT - BMD, fractures
- Odanacatib phase 3: LOFT - safety
- Challenges in drug development
- ASBMR/NOF treat-to-target task force
- Considerations
- T-score goal
- New strategies to improve care
- The future for osteoporosis
Topics Covered
- Limitations of current therapy
- New data on available medications
- Recently approved treatments
- Novel targets for intervention
- Investigational agents
- New delivery systems
- Strategies to address unmet needs
Links
Series:
Categories:
Talk Citation
Lewiecki, M. (2016, March 31). New and emerging treatments for osteoporosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 13, 2024, from https://doi.org/10.69645/DTLQ9086.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael Lewiecki acts as a consultant for Amgen, Merck, Lilly, Radius, Shire and Alexion. He also sits on the speaker's bureau for Shire and receives grants/research support as a Principal Investigator from Amgen, Merck and Lilly.
Other Talks in the Series: Bone in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
E. MICHAEL LEWIECKI:
Hello, this is Mike Lewiecki.
I'm talking to you today
about new and emerging
treatments for osteoporosis.
I'm director of New Mexico Clinical
Research and Osteoporosis Center
in Albuquerque, New Mexico,
and on the faculty of the University
of New Mexico School of Medicine.
0:21
This is my disclosure.
0:26
I'll be talking about
limitations of current therapy
for osteoporosis, new data
on available medications
for osteoporosis, recently approved
treatments, novel treatments
for intervention, investigational
agents, new delivery
systems, and strategies
to address unmet needs
in the care of osteoporosis.
0:51
These are approved
medications for osteoporosis
treatment and prevention.
We can classify drugs
at the present time
into those that reduce
bone remodeling,
typically called
antiresorptives, and those
that increase bone
remodeling, called
anabolics, or osteoanabolics.
As you can see, most drugs fall
into the antiresorptive category.
The biggest group
within that category
is the bisphosphonates,
alendronate, risedronate,
ibandronate, and zoledronic acid.
We have a selective estrogen
receptor modulator, raloxifene,
a rank ligand inhibitor, denosumab,
estrogen, nasal calcitonin,
and a combination of
estrogen and a SERM,
with conjugated estrogens
and bazedoxifene.
This is called a tissue
selective estrogen complex.
On the anabolic side,
we have one drug,
parathyroid hormone in the form
of teriparatide, which is PTH 1 to 34.
Strontium ranelate is a drug that
works by unclear mechanisms
and has sometimes been
said to have both antiresorptive
and anabolic properties.
The current treatments that
we have are pretty good.